{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:09:31Z","timestamp":1790237371788,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.hoc.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T21:16:31Z","timestamp":1781126191000},"page":"639-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecularly Guided Therapy in Hepatobiliary Cancers"],"prefix":"10.1016","volume":"40","author":[{"given":"Jorge","family":"Adeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie S.","family":"Kalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Saj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Modrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.hoc.2026.05.005_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.005_bib2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.14701\/ahbps.25-142","article-title":"Global, regional, and national burden of gallbladder and biliary tract diseases: a systematic analysis of prevalence, incidence, deaths, and disability-adjusted life years with projections to 2050","volume":"29","author":"Zheng","year":"2025","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.005_bib3","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41588-020-0708-0","article-title":"Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure","volume":"52","author":"Akdemir","year":"2020","journal-title":"Nat Genet"},{"issue":"7765","key":"10.1016\/j.hoc.2026.05.005_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","article-title":"Somatic mutations and cell identity linked by genotyping of transcriptomes","volume":"571","author":"Nam","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.005_bib5","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1055\/a-2548-0108","article-title":"Molecular landscape and treatment paradigms of hepatocellular and cholangiocarcinoma: a multinational review","volume":"63","author":"Skok","year":"2025","journal-title":"Z Gastroenterol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.005_bib6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jamasurg.2025.0242","article-title":"Molecular testing and targeted therapies in hepatobiliary cancers: a review","volume":"160","author":"Tsilimigras","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1016\/j.hoc.2026.05.005_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/bs.acr.2022.01.008","article-title":"Novel insights into molecular and immune subtypes of biliary tract cancers","volume":"156","author":"Bramel","year":"2022","journal-title":"Adv Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.005_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/hep.20375","article-title":"Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling","volume":"40","author":"Lee","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.21467","article-title":"Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets","volume":"45","author":"Boyault","year":"2007","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.hoc.2026.05.005_bib11","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal gains of VEGFA and molecular classification of hepatocellular carcinoma","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.hoc.2026.05.005_bib12","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","article-title":"Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma","volume":"69","author":"Hoshida","year":"2009","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.005_bib13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.005_bib14","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/jcp.2004.023556","article-title":"Overexpression\/amplification of HER-2\/neu is uncommon in hepatocellular carcinoma","volume":"58","author":"Xian","year":"2005","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib15","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1038\/s41598-025-87545-z","article-title":"TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jcmgh.2023.03.004","article-title":"High-resolution genomic profiling of liver cancer links etiology with mutation and epigenetic signatures","volume":"16","author":"Perez","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.005_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.005_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1326097","article-title":"Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"14","author":"Qin","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.005_bib20","article-title":"Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy","volume":"4","author":"Budhu","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.hoc.2026.05.005_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.733530","article-title":"Viral status and efficacy of immunotherapy in hepatocellular carcinoma: a systematic review with meta-analysis","volume":"12","author":"Ding","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccell.2023.11.010","article-title":"Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma","volume":"42","author":"Sun","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"Alvaro","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.hoc.2026.05.005_bib24","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.005_bib25","first-page":"504","article-title":"Molecular and histological profiles and relevant imaging signatures of intrahepatic cholangiocarcinoma","volume":"13","author":"Huang","year":"2025","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.005_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9840","article-title":"KRAS allelic variants in biliary tract cancers","volume":"7","author":"Moffat","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.005_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105306","article-title":"Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers","volume":"10","author":"Iida","year":"2025","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.005_bib28","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.31110","article-title":"Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals therapeutic opportunities","volume":"72","author":"Goeppert","year":"2020","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.005_bib29","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"issue":"41","key":"10.1016\/j.hoc.2026.05.005_bib30","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2423536122","article-title":"Natural history of liver fluke infection underpins epidemiological patterns of biliary cancer","volume":"122","author":"Crellen","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hoc.2026.05.005_bib31","article-title":"Intrahepatic cholangiocarcinoma: genomic heterogeneity between eastern and Western patients","volume":"4","author":"Cao","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.hoc.2026.05.005_bib32","article-title":"Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures","volume":"6","author":"Mody","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.005_bib33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.005_bib34","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1038\/s41588-025-02236-9","article-title":"Multi-omic analysis of gallbladder cancer identifies distinct tumor microenvironments associated with disease progression","volume":"57","author":"Zhou","year":"2025","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.005_bib35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"20","key":"10.1016\/j.hoc.2026.05.005_bib36","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.005_bib37","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa Ghassan","year":"2022","journal-title":"NEJM Evid"},{"issue":"10492","key":"10.1016\/j.hoc.2026.05.005_bib38","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (checkMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.005_bib39","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"10126","key":"10.1016\/j.hoc.2026.05.005_bib40","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"10064","key":"10.1016\/j.hoc.2026.05.005_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.005_bib43","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2026.05.005_bib44","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2217\/fon-2019-0097","article-title":"RATIONALE 301 study: Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma","volume":"15","author":"Qin","year":"2019","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.005_bib45","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10408","key":"10.1016\/j.hoc.2026.05.005_bib46","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.005_bib47","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.005_bib48","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S2468-1253(25)00059-7","article-title":"Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial","volume":"10","author":"Shi","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.005_bib49","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","article-title":"Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.hoc.2026.05.005_bib50","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.005_bib51","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/14728222.2024.2416975","article-title":"Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy","volume":"28","author":"Couzinet","year":"2024","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.005_bib52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","article-title":"Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma","volume":"65","author":"Abou-Alfa","year":"2016","journal-title":"J Hepatol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.005_bib53","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2024.42.16_suppl.4019","article-title":"Phase I study of C-CAR031, a GPC3-specific TGF\u03b2RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.005_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104165","article-title":"9O phase I\/II, open-label, first-in-human study of the anti-GPC3 T cell engager SAR444200 in patients with advanced solid tumors: updated safety and pharmacokinetic analysis","volume":"10","author":"Almhanna","year":"2025","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.005_bib55","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","article-title":"A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","volume":"41","author":"Chan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.005_bib57","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oncolo\/oyae011","article-title":"Methylthioadenosine phosphorylase genomic loss in advanced gastrointestinal cancers","volume":"29","author":"Ngoi","year":"2024","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.005_bib58","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154515","article-title":"\u03b2-Catenin signaling in hepatocellular carcinoma","volume":"132","author":"Xu","year":"2022","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib59","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1038\/s41467-025-60457-2","article-title":"Precision targeting of \u03b2-catenin induces tumor reprogramming and immunity in hepatocellular cancers","volume":"16","author":"Lehrich","year":"2025","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.005_bib60","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.005_bib61","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.005_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110777","article-title":"FGFR2 might be a promising therapeutic target for some solid tumors: analysis of 1312 cancers with FGFR2 abnormalities","volume":"26","author":"Nishikubo","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"2_suppl","key":"10.1016\/j.hoc.2026.05.005_bib63","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO.2026.44.2_suppl.476","article-title":"Efficacy and safety of lirafugratinib in FGFRi-na\u00efve cholangiocarcinoma (CCA) patients harboring FGFR2 fusions\/rearrangements (FGFR2 f\/r)","volume":"44","author":"Hollebecque","year":"2026","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.005_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.005_bib65","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.005_bib66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"3_suppl","key":"10.1016\/j.hoc.2026.05.005_bib67","doi-asserted-by":"crossref","first-page":"TPS572","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS572","article-title":"FOENIX-CCA4: a phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions\/rearrangements","volume":"42","author":"Macarulla","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.005_bib68","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2026.05.005_bib69","article-title":"Erdafitinib in patients with FGFR-altered advanced or metastatic cholangiocarcinoma","author":"Pant","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib70","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-Altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.005_bib71","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2023.10.041","article-title":"Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma","volume":"80","author":"DiPeri","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.hoc.2026.05.005_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1527484","article-title":"Case report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A\/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion","volume":"15","author":"Ballin","year":"2025","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.005_bib73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2468-1253(25)00230-4","article-title":"Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial","volume":"11","author":"Javle","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2026.05.005_bib74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/liv.14100","article-title":"Medical treatment for cholangiocarcinoma","volume":"39","author":"Adeva","year":"2019","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.005_bib75","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.005_bib76","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2026.05.005_bib77","doi-asserted-by":"crossref","unstructured":"Pauff JM, Papadopoulos KP, Janku F, et al. A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors. Journal of Clinical Oncology.39(3_suppl):TPS350.","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS350"},{"key":"10.1016\/j.hoc.2026.05.005_bib78","article-title":"MAPK pathway mutations emerge in Mutant-IDH1 inhibitor-resistant cholangiocarcinoma and attenuate the interferon response","author":"Wan","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.005_bib79","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","article-title":"Mutant IDH inhibits IFN\u03b3-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2026.05.005_bib80","article-title":"Comprehensive immunogenomic profiling of IDH1-\/2-Altered cholangiocarcinoma","volume":"8","author":"Makawita","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"2_suppl","key":"10.1016\/j.hoc.2026.05.005_bib81","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2026.44.2_suppl.558","article-title":"Results from the safety lead-in for a phase 1b\/2 study of ivosidenib plus durvalumab and gemcitabine\/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation","volume":"44","author":"Oh","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib82","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.005_bib83","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.23.01193","article-title":"Trastuzumab plus gemcitabine-cisplatin for treatment-na\u00efve human epidermal growth factor receptor 2-Positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB)","volume":"42","author":"Ostwal","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.005_bib84","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.hoc.2026.05.005_bib85","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-Positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.005_bib86","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib87","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.005_bib88","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2026.05.005_bib89","article-title":"Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: results from the targeted agent and profiling utilization registry study","volume":"7","author":"Meric-Bernstam","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.005_bib90","article-title":"Phase I clinical trial evaluating safety, tolerability, and early activity of exarafenib (KIN-2787), a highly selective Pan-RAF inhibitor, in BRAF-altered solid tumors or NRAS-mutant melanoma","author":"Gambardella","year":"2026","journal-title":"JCO Oncology Advances"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.005_bib91","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.005_bib92","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.005_bib93","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41591-025-04079-7","article-title":"Repotrectinib in NTRK fusion\u2013positive advanced solid tumors: a phase 1\/2 trial","volume":"32","author":"Besse","year":"2026","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.005_bib94","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.005_bib95","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.hoc.2026.05.005_bib96","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.005_bib97","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.005_bib98","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.005_bib99","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2024.42.16_suppl.3007","article-title":"Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors","volume":"42","author":"Heist","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.005_bib100","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4143\/crt.2019.370","article-title":"Prevalence and clinicopathological significance of MET overexpression and gene amplification in patients with gallbladder carcinoma","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.005_bib101","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/oncolo\/oyae265","article-title":"Exceptional sustained long-term complete response to tepotinib in a MET-Amplified advanced intrahepatic biliary tract cancer failing durvalumab plus cisplatin and gemcitabine","volume":"29","author":"Reichinger","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib102","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/15384047.2022.2029128","article-title":"Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature","volume":"23","author":"Lefler","year":"2022","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.hoc.2026.05.005_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1254026","article-title":"Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.005_bib104","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oncolo\/oyae011","article-title":"Methylthioadenosine phosphorylase genomic loss in advanced gastrointestinal cancers","volume":"29","author":"Ngoi","year":"2024","journal-title":"Oncologist"},{"issue":"3_suppl","key":"10.1016\/j.hoc.2026.05.005_bib105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2024.42.3_suppl.487","article-title":"Efficacy and safety of brigimadlin (BI 907828), an MDM2\u2013p53 antagonist, in patients (pts) with advanced biliary tract cancer: data from two phase Ia\/Ib dose-escalation\/expansion trials","volume":"42","author":"Macarulla","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.005_bib106","article-title":"Claudin-18.2 and Trop-2 as emerging biomarkers in biliary tract cancers: expression analysis and therapeutic potential","author":"Shin","year":"2025","journal-title":"Target Oncol"},{"key":"10.1016\/j.hoc.2026.05.005_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.05.400","article-title":"385TiP AZD0901 monotherapy in patients (pts) with advanced biliary tract cancer (BTC) expressing claudin18.2 (CLDN18.2): CLARITY-PanTumour01 substudy 3","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.005_bib108","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.005_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1705162","article-title":"Liquid biopsy in biliary tract cancers: early diagnosis, precision therapy, and prognostic evaluation","volume":"15","author":"Wu","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.hoc.2026.05.005_bib110","article-title":"Fusion challenges in solid tumors: shaping the landscape of cancer care in precision medicine","volume":"8","author":"Ahmed","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.hoc.2026.05.005_bib111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00324","article-title":"Circulating tumor DNA profiling of advanced biliary tract cancers","volume":"3","author":"Mody","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.005_bib112","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000433518","article-title":"Translational genomics in Low- and middle-income countries: opportunities and challenges","volume":"18","author":"Tekola-Ayele","year":"2015","journal-title":"Public Health Genom"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.005_bib113","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jmoldx.2025.08.011","article-title":"Developing consensus for a more provider-friendly next-generation sequencing molecular biomarker report: a joint consensus recommendation of the association for molecular pathology and college of American pathologists","volume":"27","author":"Gibson","year":"2025","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.005_bib114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10238-025-01965-9","article-title":"AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions","volume":"26","author":"Hsu","year":"2025","journal-title":"Clin Exp Med"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.005_bib115","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1200\/JCO.24.00662","article-title":"Selection of germline genetic testing panels in patients with cancer: ASCO guideline","volume":"42","author":"Tung","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:31:04Z","timestamp":1784579464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0889858826000456"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecularly Guided Therapy in Hepatobiliary Cancers","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}